Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

Hepatitis C — pipeline update

Nature Reviews Drug Discovery volume 10, pages 93–94 (2011)Cite this article

Subjects

The recently concluded sixty-first annual meeting of the American Association for the Study of Liver Diseases (AASLD) provided a broad overview of the pipeline of novel drugs for the treatment of CHC2. It is clear that this field is on the brink of significant improvements to the SOC that should follow the highly anticipated approval of the first direct antiviral agents (DAAs), telaprevir (Vertex/Johnson & Johnson/Mitsubishi) and boceprevir (Merck), in 2011.

Telaprevir versus boceprevir

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Antiviral activities of selected direct antiviral agents.

References

  1. Ghany, M. G., Strader, D. B., Thomas, D. L. & Seeff, L. B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49, 1335–1374 (2009).

    Article  CAS  Google Scholar 

  2. The 61st Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2010. Hepatology 52 (Suppl. S1), iiA–ivA, 1A–1352A (2010).

  3. Sarrazin, C. & Zeuzem, S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138, 447–462 (2010).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Irena Melnikova is a Director of Scouting and Partnering at Sanofi-Aventis, 270 Albany St., Massachusetts 02139, USA. irena.melnikova@sanofi-aventis.com,

    Irena Melnikova

Authors
  1. Irena Melnikova
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Related links

Related links

FURTHER INFORMATION

ClinicalTrials.gov

HCV New Drug Research

Thomson Pharma Partnering

Rights and permissions

Reprints and permissions

About this article

Cite this article

Melnikova, I. Hepatitis C — pipeline update. Nat Rev Drug Discov 10, 93–94 (2011). https://doi.org/10.1038/nrd3361

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3361

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing